The Patented Medicine Prices Review Board (PMPRB) announced the reappointment of Dr. Mitchell Levine of Hamilton, Ontario as Vice-chairperson of the Board for a second five-year term. Dr. Levine is a Professor in the departments of Medicine and Clinical Epidemiology and Biostatistics in the Faculty of Health Sciences at McMaster ... Read More
23
Nov2016
09
Nov2016
Owing to new developments and growing stakeholder interest, PDCI and H3 have now completed a second private payer PLA survey. In total, 30 complete responses were received from 25 individual pharmaceutical companies and five different private payer representatives. With more respondents this year from manufacturers and representation from private payers, ... Read More
31
Oct2016
The Canadian Association for Healthcare Reimbursement (CAHR) is holding a one-day event to explore a national approach to pharma policy considering international and Canadian perspectives. The entire day gives attendees excellent opportunities to hear from payers, pharma, patient-led organizations and providers, including PDCI’s own Courtney Abunassar.
Related to this topic, the ... Read More
20
Oct2016
INESSS Upcoming Meetings with Manufacturers – June 2017 “Liste des médicaments”
INESSS is offering an opportunity for in-person meetings to manufacturers who have filed a submission by the November 25, 2016 deadline for drugs to be listed on the June 2017 “Liste des médicaments". These meetings will be held between December ... Read More
13
Oct2016
The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of September 30, 2016:
37 negotiations are currently underway with no new files added since the last update of August 31, 2016.
118 joint negotiations have been completed with 4 files successfully negotiated ... Read More
11
Oct2016
Effective November 1, 2016, the ministry is introducing the application of generic substitution to the Exceptional Access Program (EAP).
Under this new policy, if an EAP drug has an interchangeable generic product designated through the Off-Formulary Interchangeable (OFI) mechanism, the ministry will only approve the funding of the generic product. Where ... Read More
04
Oct2016
The Ontario Public Drug Programs (OPDP) is publishing an addendum (Addendum #1) to the Ontario Guidelines for Drug Submission and Evaluation (Guidelines) to assist the manufacturers in making drug submissions to the OPDP. Addendum #1 contains information about the regulatory amendments that were recently approved by the Ontario government and ... Read More
28
Sep2016
Alberta Health amended their price policy on September 26, 2016 to come into effect on October 1, 2016. The following amendments were made:
Amendment to the Maximum Allowable (MAC) Price Policy of the Alberta Price Policy
Effective October 1, 2016, the MAC Price Policy, section 2-14, will be amended to include eligible ... Read More
26
Sep2016
Recent amendments have been made to the Ontario Regulation 201/96 under the Ontario Drug Benefit Act (‘ODBA Regulation’) and to Regulation 935 under the Drug Interchangeability and Dispensing Fee Act (‘DIDFA Regulation’). The amendments have been approved by the Ontario Government and come into force on October 1, 2016.
A notice ... Read More
20
Sep2016
To help drug manufacturers prepare drug submissions, the Ministry of Health and Long-Term Care has updated its Ontario Guidelines for Drug Submission and Evaluation (Guidelines).
The Guidelines take effect on October 6, 2016. All submissions received on or after this date must comply.
The updated Guidelines reflect current regulatory and policy requirements ... Read More